Researchers at Stanford Medicine and their collaborators recently developed a nasal vaccine that shields against various respiratory viruses, bacteria, and allergens. Consequently, a single vaccine could potentially replace multiple yearly shots for seasonal illnesses if similar results are achieved in people.
Furthermore, this innovation would provide rapid protection if a dangerous new pandemic virus suddenly emerges in the global population.
Read More Nasal Spray Offers New Hope for Alzheimer’s
Scientific Findings from the Stanford Study
The findings, published in Science, show that vaccinated mice were protected from SARS-CoV-2 and other coronaviruses. Additionally, the mice resisted common hospital-acquired infections like Staphylococcus aureus and Acinetobacter baumannii during the testing phase. The nasal spray also blocked reactions to house dust mites, which are a very common respiratory allergen for many people.
According to senior author Bali Pulendran, the level of protection across these diverse threats exceeded all initial research expectations. The study’s lead author, Haibo Zhang, serves as a postdoctoral scholar in Pulendran’s laboratory at Stanford Medicine.
Why Traditional Vaccines Need Modern Updating
This experimental vaccine works very differently from traditional vaccines that have relied on antigen specificity for over 200 years. Standard vaccines present the immune system with a recognizable piece of a pathogen so the body can attack it later. However, many pathogens evolve quickly and change their surface structures, which causes previously effective vaccines to lose their potency. This rapid mutation is the primary reason why updated COVID-19 boosters and annual flu shots are currently necessary. Because viruses change like a leopard changing its spots, researchers aimed to create a broader and more resilient defense.
Replicating Nature’s Immune Signals
The new vaccine formulation, currently called GLA-3M-052-LS+OVA, functions by replicating vital signals between various immune cells. Specifically, it mimics the T cell signals that naturally stimulate the innate immune cells found deep within the lungs. The mixture also includes a harmless egg protein known as ovalbumin to help sustain this protective state. This protein draws T cells into the lung tissues to maintain a boosted immune response for several months. Consequently, the lungs remain on high alert to neutralize any incoming pathogens before they can cause severe illness.
The “Double Whammy” of Protection
In recent studies, mice received the vaccine as simple droplets placed directly into their sensitive nasal passages. Researchers observed that three doses provided robust protection against SARS-CoV-2 and other coronaviruses for at least three months. Dr. Pulendran describes this powerful effect as a “double whammy” for the body’s natural defense system. First, the sustained innate response reduces viral levels in the lungs by a staggering 700-fold. Second, the vaccine enables the adaptive immune system to launch virus-specific antibodies in just three short days.
Defending Against Bacteria and Allergens
Beyond fighting viruses, the universal vaccine also protects the respiratory system from dangerous bacterial pathogens and common household allergens. Vaccinated mice successfully resisted Staphylococcus aureus and other hospital-acquired infections during the extensive three-month testing period. Furthermore, the team discovered that the vaccine prevents allergic asthma reactions caused by common house dust mites. Unvaccinated mice developed heavy mucus in their airways, whereas vaccinated mice maintained clear and healthy breathing passages. This unique ability to block diverse threats confirms the vaccine’s potential as a truly universal respiratory shield.
The Roadmap to Human Application
The next critical step for this research involves a Phase I safety trial to test the vaccine in humans. If these initial results are positive, larger studies will follow to confirm the spray’s effectiveness across broader populations. Experts estimate that two doses of the nasal spray could be sufficient to protect a person for an entire season. With adequate funding, this universal respiratory vaccine could be available to the public within five to seven years. Such a breakthrough would transform medical practice by protecting people from the common cold and future pandemics simultaneously.
Read More 5,000-Year-Old Ice Cave Bacterium That Resists Modern Antibiotics
Expert Q&A: The Future of Immunisation
Q: How does this new vaccine differ from traditional shots?
Traditional vaccines target one specific virus, while this “universal” version protects against many unrelated pathogens at the same time.
Q: Could this spray protect us from future pandemics?
Yes, researchers believe this technology could provide rapid protection against new viruses before specific vaccines are even developed.
Frequently Asked Questions (FAQ)
What is the “paradigm of vaccinology” mentioned by the researchers?
It refers to the 230-year-old strategy of using specific antigens to train the immune system against one particular disease.
Was this universal vaccine tested on humans yet?
The current results are based on a successful mouse study, and further research is needed for human application.
What specific bacteria did the vaccine protect against?
The study showed protection against Staphylococcus aureus and Acinetobacter baumannii, which are common and dangerous hospital-acquired infections.
Why was this idea previously considered unrealistic?
Most experts believed it was impossible for one single vaccine to defend against entirely different types of unrelated pathogens.
